Dutton Associates Featured Company: Viral Genetics Inc. (VRAL.PK)
Source: http://Blog.QualityStocks.net/?p=10442Posted on Tuesday, June 3rd, 2008 | In Current Market News, OTCBB Markets, Small & Micro Cap, Stocks to Watch
Viral Genetics Inc. is a biotechnology company with a focus on protein-based therapeutic and diagnostic products with applications in infectious disease, autoimmune conditions, and immunological deficiency. The company and its management team are key players in the fight against HIV/AIDS, infectious disease, and autoimmune deficiency. Viral Genetics has been working since 1995 to find a cure for HIV/AIDS and is based in Azusa, California.
VRAL develops its products based on thymus nuclear protein (TNP), a processed extract of mammalian thymus tissue. It has developed a lead product, VGV-1, which is a suspension of TNP in alum adjuvant for the treatment of HIV infection and AIDS. VGV-1 is currently in the preclinical stage of development in the United States, but outside of the USA it is in later stage development. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment.
Over the past 13 years, Viral Genetics has performed five human clinical trials in South Africa, China, Bulgaria, and Mexico utilizing VGV-1, and each time the results have suggested a significant decrease in the HIV viral load. The HIV market has historically had high growth rates because of the desperate need for a cure. According to the World Health Organization’s annual report in 2007, the number of people infected with HIV or AIDS globally had reached 33.2 million. With such a desperate need for a cure, companies like Viral Genetics are vital to the global market as the anticipation for a cure to this epidemic grows by the day.
Let us hear your thoughts: Viral Genetics Inc. Message Board
Last 5 posts by QualityStocks
- November 23rd CEOcast Weekly Newsletter - November 23rd, 2009
- Longwei Petroleum Investment Holdings Ltd. (LPHI) Reports Strong Third Quarter - November 23rd, 2009
- An Opportunity to Get there First in the Media Space - November 23rd, 2009
- Akeena Solar, Inc. (AKNS) Partners with Highland Solar Achieving Canadian Market Penetration - November 23rd, 2009
- Cardio Vascular Medical Device Corp. (CVSL.OB) Applying for Patents in Europe, Canada, and Far East - November 23rd, 2009
Adjuvant, Autoimmune Conditions, Autoimmune Deficiency, Azusa California, biotech, Biotechnology Company, Current Market News, Desperate Need, Diagnostic Products, Dutton Associates, Hiv Aids, Hiv Infection And Aids, Hiv Viral Load, Novel Mechanism, Nuclear Protein, OTCBB Markets, Small & Micro Cap, Stage Development, Stage Of Development, Stocks to Watch, Thymus, Thymus Tissue, Treatment Of Hiv, Viral Genetics Inc, World Health Organization
 About QualityStocks (http://QualityStocks.net)
Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. We believe strong management and vision for the future are crucial for any company to be successful. Timing is everything and we help investors succeed by providing an objective, broad-based view of the SmallCap markets on a daily basis. Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.